Argyle Capital Management Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 16.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,467 shares of the company’s stock after selling 3,715 shares during the period. Eli Lilly and Company accounts for about 4.5% of Argyle Capital Management Inc.’s investment portfolio, making the stock its 2nd biggest holding. Argyle Capital Management Inc.’s holdings in Eli Lilly and Company were worth $10,765,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of LLY. International Assets Investment Management LLC grew its holdings in Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares during the period. Sapient Capital LLC acquired a new position in Eli Lilly and Company during the fourth quarter valued at approximately $617,312,000. J.P. Morgan Private Wealth Advisors LLC acquired a new position in Eli Lilly and Company during the third quarter valued at approximately $435,736,000. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after buying an additional 659,838 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Eli Lilly and Company by 24.2% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock valued at $1,778,362,000 after buying an additional 645,473 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.
Insider Buying and Selling
In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by insiders.
Analyst Ratings Changes
Check Out Our Latest Analysis on LLY
Eli Lilly and Company Stock Performance
Shares of LLY traded up $8.64 during trading hours on Friday, hitting $733.51. The company had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. The firm has a market cap of $696.95 billion, a price-to-earnings ratio of 126.47, a PEG ratio of 1.60 and a beta of 0.34. The business has a fifty day moving average of $761.79 and a 200-day moving average of $667.10. Eli Lilly and Company has a 12 month low of $380.77 and a 12 month high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue was up 28.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.09 earnings per share. Equities analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More
- Five stocks we like better than Eli Lilly and Company
- What Are Dividends? Buy the Best Dividend Stocks
- Snap Crackles and Pops on Surprise Profit and Raised Guidance
- Energy and Oil Stocks Explained
- MarketBeat Week in Review – 4/22 – 4/26
- Dividend Capture Strategy: What You Need to Know
- 3 Stocks Leading the U.S. Agriculture Comeback
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.